OMS721

narsoplimab · Omeros Corporation

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for OMS721, covering 2015-04-15 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 [Phase 2]